← Leaderboards
Christopher Shen
Aleutian Therapeutics, Inc.
$985,013
Attributed
$985,013
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$985,013 · 3
By mechanism
R41$985,013 · 3
Top collaborators
No co-investigators on record.
Others in their field
Other Rising Stars on “In Vivo”
- Michael Difilippantonio · Leidos Biomedical Research, Inc.$22,364,766
- Sabrina Paganoni · Massachusetts General Hospital$17,050,216
- Suma Babu · Massachusetts General Hospital$17,050,216
- Kevin V Grimes · Stanford University$14,783,804
- Xuping Xie · University Of Texas Med Br Galveston$13,737,799
- Heinz Ernst Moser · University Of Texas Med Br Galveston$12,973,432
Research focus
In VivoPhase 1 StudyImmune EvasionInsulin-Dependent Diabetes MellitusNatural Killer CellsNew TechnologyDesignImmuneCell TherapyInnovationCurative TreatmentsMediatingAnimalsCostCell KillingComplementCell LineGenerationsAllogenicCellsImmunocompetentImmunosuppressionAutoimmune DiseasesPluripotent Stem Cells
Grant awards (3)
Development of an immune evasive stem cell line for Type 1 diabetes regenerative therapy$372,067
R41 · FY2025 · DK · contact PI
Development of immune evasive strategies for allogeneic cell replacement therapies$307,091
R41 · FY2025 · AI · contact PI
Development of a gene edited platform to enable human allogeneic cell replacement therapy$305,855
R41 · FY2025 · AI · contact PI